Biocon has informed that the US FDA conducted a periodic cGMP inspection of its Drug Substance manufacturing site at Bangalore Campus from Sep 17 - 21, 2018. The weeklong audit concluded without any observations and no Form 483 was issued. The successful audit of this site reflects the strong commitment to cGMP compliance.
The above information is a part of company’s filings submitted to BSE.